BI Asset Management Fondsmaeglerselskab A S Has $171,000 Holdings in ADMA Biologics Inc $ADMA

Key Points

• BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in ADMA Biologics by 92.2%, holding only 8,606 shares after selling 101,457 shares during the first quarter.
• Despite this reduction, other institutional investors have increased their positions, with New York State Teachers Retirement System boosting its stake by 96.2% and GAMMA Investing LLC raising theirs by 251.6%.
• ADMA Biologics reported a 13.8% year-over-year increase in revenue, totaling $121.98 million, and also exceeded analysts' EPS expectations by reporting $0.15 for the quarter.

BI Asset Management Fondsmaeglerselskab A S reduced its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 92.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,606 shares of the biotechnology company's stock after selling 101,457 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in ADMA Biologics were worth $171,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. New York State Teachers Retirement System boosted its holdings in shares of ADMA Biologics by 96.2% during the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after buying an additional 108,800 shares during the period. GAMMA Investing LLC boosted its holdings in shares of ADMA Biologics by 251.6% during the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after buying an additional 4,715 shares during the period. Concurrent Investment Advisors LLC bought a new stake in ADMA Biologics in the 1st quarter valued at $201,000. Ameriprise Financial Inc. boosted its holdings in ADMA Biologics by 14.1% in the 4th quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock valued at $12,274,000 after purchasing an additional 88,542 shares during the period. Finally, Penserra Capital Management LLC bought a new stake in ADMA Biologics in the 1st quarter valued at $2,293,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Raymond James Financial increased their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, ADMA Biologics currently has a consensus rating of "Buy" and an average target price of $27.67.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.12 during mid-day trading on Friday, reaching $17.26. The company's stock had a trading volume of 2,527,726 shares, compared to its average volume of 3,388,413. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a market cap of $4.12 billion, a P/E ratio of 20.07 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The firm's 50-day moving average is $17.76 and its two-hundred day moving average is $18.91.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm's revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. On average, research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director owned 94,830 shares in the company, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold 455,621 shares of company stock worth $9,461,633 in the last quarter. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.